Amneal Pharmaceuticals (AMRX) announced that the FDA has approved memantine/donepezil 14-10 mg and 28-10 mg extended-release capsules, which references Abbvie’s Namzaric, and Everolimus 2 mg, 3 mg and 5 mg extended-release capsules, which references Novartis’ Afinitor Disperz. In addition, the FDA has granted tentative approval to Amneal’s rifaximin 550 mg oral tablets, which references Bausch Health’s Xifaxan. The FDA approval was tentative as this product is involved in litigation.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRX:
- Amneal receives FDA tentative approval for ANDA for rifaximin
- Amneal Pharmaceuticals backs prior FY24 EPS view 57c-63c, consensus 61c
- Amneal Pharmaceuticals Maintains Transparency with SEC Filing
- Amneal Pharmaceuticals director Patel sells 62,590 class A shares
- Appeals court sides with Amneal over Teva in inhaler patent fight